E Fund Management’s Inovio Pharmaceuticals INO Stock Holding History

E Fund Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,774	Closed	-$106K	–	326
2023 Q1	$106K	Sell	10,774 -533	-5%	-$9.09K	0.01%	321
2022 Q4	$212K	Buy	11,307 +667	+6%	+$15.1K	0.02%	293
2022 Q3	$220K	Sell	10,640 -3,316	-24%	-$84.9K	0.02%	288
2022 Q2	$290K	Buy	13,956 +7,014	+101%	+$198K	0.03%	238
2022 Q1	$299K	Buy	6,942 +4,561	+192%	+$205K	0.01%	196
2021 Q4	$143K	Buy	2,381 +574	+32%	+$46K	0.01%	279
2021 Q3	$155K	Buy	+1,807	New	+$181K	0.01%	249
2021 Q1	$123K	Buy	+1,100	New	+$145K	0.01%	233

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

E Fund Management's INO Position: Q2 2023 in Review

E Fund Management sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 10,774 shares — an estimated $106K sold.

E Fund Management first reported a position in INO in Q1 2021 and held it in 8 quarters. The position peaked at $299K in Q1 2022. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

E Fund Management reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
E Fund Management sold 10,774 Inovio Pharmaceuticals shares in Q2 2023, an estimated $106K.
E Fund Management first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 8 quarters.
E Fund Management's Inovio Pharmaceuticals position peaked at $299K in Q1 2022.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on E Fund Management's 13F filing for Q2 2023, filed 11 Aug 2023.